Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1173-1184

  Tolcher, A W ^a   Cowan, K H ^a   Solomon, D ^a   Ognibene, F ^a   Goldspiel, B ^a   Chang, R ^a   Noone, M H ^a   Denicoff, A M ^a   Barnes, C S ^a   Gossard, M R ^a   Fetsch, P A ^a   Berg, S L ^a   Balis, F M ^a   Venzon, D J ^a   O'Shaughnessy, J A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VERAPAMIL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MAXIMUM ALLOWABLE CONCENTRATION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 9244232271     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1173     Document Type: Article

References (44)

1. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62:385-427, 1993
2. Endicott JA, Ling V: The biochemistry of P-glycoprotein mediated multidrug resistance. Ann Rev Biochem 58:137-171, 1989
3. Chen CJ, Chin JE, Ueda K, et al: Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389, 1986
4. Gros P, Croop J, Housman D: Mammalian multidrug resistance gene: Complete cDNA sequence indicates homology to bacterial transport proteins. Cell 47:371-380, 1986
5. Sanfilippo O, Ronchi E, DeMarco C, et al: Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur J Cancer 27:155-158, 1991
6. Ro J, Sahin A, Ro JY: Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21:787-791, 1990
7. Schnieder J, Bak M, Efferth TH, et al: P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 60:815-818, 1989
8. Holmes F, Walters R, Theriault R, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
9. Reichman B, Seidman A, Crown J, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
10. Vermorken J, Huizing M, Liefting A, et al: High-dose Taxol (HDT) with G-CSF in patients with advanced breast cancer (ABC) refractory to anthracycline (ANT) therapy. Eur J Cancer 29A:83, 1993 (suppl 6, abstr 435)
11. Nabholtz J, Gelmon K, Bontenbal M, et al: Randomized trial two doses of Taxol in metastatic breast cancer. Proc Am Soc Clin Oncol 12:60, 1993 (abstr 42)
12. Horwitz S, Lothstein L, Manfredi J, et al: Taxol: Mechanisms of action and resistance. Ann NY Acad Sci 466:733-744, 1986
13. Tsuruo T, Iida H, Tsukagoshi S, et al: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972, 1981
14. Yusa K, Tsuruo T: Reversal mechanism of multidrug resistance by verapamil. Direct binding of verapamil to P-glycoprotein specific sites and transport of verapamil outward across the plasma membrane of K562 ADM cells. Cancer Res 49:5002-5006, 1989
15. Schuurhuis G, Broxterman H, Cervantes A: Quantitative determination of factors contributing to doxorubicin resistance in multidrug resistant cells. J Natl Cancer Inst 81:1887-1892, 1989
16. Dalton W, Grogan P, Meltzer P, et al: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415-424, 1989
17. Benson A, Trump D, Koeller J, et al: Phase I study of vinblastine and verapamil given by concurrent IV infusion. Cancer Treat Rep 69:795-799, 1985
18. Ozols R, Cunnion R, Klecker R, et al: Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641-647, 1987
19. Echizen H, Brecht T, Niedergesass S, et al: The effect of dextro-, levo-, and racemic verapamil on atrioventriclar conduction in humans. Am Heart J 109:210-217, 1985
20. Haubermann K, Benz B, Gekeler V, et al: Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur J Clin Pharmacol 40:53-59, 1991
21. Mickisch G, Merlino G, Aiken P, et al: New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the MDR1 gene. J Urol 146:447-453, 1991
22. Ahmed JH, Godden J, Meredith PA, Elliott HL: R-verapamil: Pharmacokinetics and effects on PR interval, blood pressure and heart rate. Br J Clin Pharmacol 36:93-98, 1993
23. Vogelgesang B, Echizen H, Schmidt E, et al: Stereoselective first-pass metabolism of highly cleared drugs: Studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol 18:733-740, 1984
24. Wilson W, Bates S, Kang Y, et al: Reversal of multidrug resistance (mdr-1) expression in patients with lymphoma refractory to EPOCH chemotherapy. Proc Am Assoc Cancer Res 34:212, 1993 (abstr 1266)
25. Harapat SR, Kates RE: High-performance liquid chromatographic analysis of verapamil: Simultaneous quantitation of verapamil and its active metabolite, norverapamil. J Chromatography 181:484-489, 1980
26. Koch GG: The use of non-parametric methods in the statistical analysis of the 2-period change-over design. Biometrics 28:577-584, 1972
27. Rowinsky E, Eisenhauer E, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15, 1993 (suppl 3)
28. McGuire W, Rowinsky E, Neil B, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
29. Berg SL, Tolcher A, O'Shaughnessy JA, et al: Effect of r-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 13:2039-2042, 1995
30. Hendrick AM, Harris AL, Cantwell: Verapamil with mitoxantrone for advanced ovarian cancer: A negative phase II trial. Ann Oncol 2:71-72, 1991
31. Dalmark M, Pals H, Johnsen AH: Doxorubicin in combination with verapamil in advanced colorectal cancer. A phase II trial. Acta Oncol 30:23-26, 1991
32. Presant CA, Kennedy PS, Wiseman C, et al: Verapamil reversal of clinical doxorubicin resistance in human cancer. Am J Oncol 9:355-357, 1986
33. Bissett D, Kerr DJ, Cassidy J, et al: Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 64:1168-1171, 1991
34. Finucci G, Padrini R, Piovan D, et al: Verapamil pharmacokinetics and liver function in patients with cirrhosis. Int J Clin Pharm Res 8:123-126, 1988
35. Kerr DJ, Graham J, Cummings J, et al: The effect of verapamil on the pharmacokinetics of Adriamycin. Cancer Chemother Pharmacol 18:239-242, 1986
36. Lum BL, Kaubisch S, Yahanda AM, et al: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642, 1992
37. Bartlett NL, Lum BL, Fisher GA, et al: Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12:835-842, 1994
38. Chaudhary P, Roninson I: Expression and activity of P-glycoprolein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85-94, 1991
39. Drach D, Zhao S, Drach J, et al: Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729-2734, 1992
40. Horton JK, Thimmaiah KN, Houghton JA, et al: Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem Pharmacol 38:1727-1736, 1989
41. Verrelle P, Meissonnier F, Fonck Y, et al: Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83:111-115, 1991
42. Wishart G, Plumb J, Going J, et al: P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 62:758-761, 1990
43. Salmon S, Grogan T, Miller T, et al: Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 81:696-701, 1989
44. Wilson WH, Berg S, Bryant GB, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II study of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994